Aurobindo receives FDA approval for generic Activella
Etyqa tablets are indicated as a treatment for moderate to severe vasomotor symptoms due to menopause.
Aurobindo has received clearance from the Food and Drug Administration for Etyqa tablets, 0.5 mg/0.1 mg and 1 mg/0.5 mg, which are the generic of Amneal’s Activella.
Etyqa tablets are indicated as a treatment of moderate to severe vasomotor symptoms due to menopause, treatment of moderate to severe symptoms of vulva and vaginal atrophy due to menopause prevention of postmenopausal osteoporosis.
[Read more: Aurobindo receives FDA approval for 3 generics]
Etyqa tablets have a market value of roughly $34.5 million for the 12 months ending April 2023, as per IQVIA.
[Read more: Aurobindo obtains FDA OK for 2 generics]